(Adds details on earnings, outlook)
April 28 (Reuters) - GSK topped analysts'
expectations for first-quarter earnings as more people visited
clinics for critical treatments such as HIV and routine shots
once COVID-19 curbs eased, adding on Wednesday that plans to
split into two were "well underway".
Turnover for the three months to March fell 15% to 7.42
billion pounds ($10.28 billion) at constant currency rates,
while adjusted earnings stood at 22.9 pence per share, GSK, the
world's biggest vaccine maker by sales, said.
Analysts had expected adjusted earnings of 21.9 pence per
share and sales of 7.83 billion pounds, a company-compiled
consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus
of 17 analysts showed.
GSK said it would provide details on its plan to separate
into an over-the-counter products business and another for
prescription medicines and vaccines in June.
($1 = 0.7215 pounds)
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger
in Frankfurt; Editing by Jason Neely and Alexander Smith)
Glaxosmithkline (GSK)